Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lisinopril + hydrochlorothiazide is a fixed-dose combination medication used to treat high blood pressure (hypertension). It combines two active ingredients: * Lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, which works by blocking the formation of angiotensin II, a substance that causes blood vessels to constrict. This leads to relaxation of blood vessels and lower blood pressure. * Hydrochlorothiazide, a thiazide diuretic ("water pill"), which helps the kidneys remove excess water and sodium from the body through urine, further lowering blood pressure. This combination is indicated for patients whose blood pressure is not adequately controlled with monotherapy. Lowering high blood pressure reduces the risk of stroke, heart attack, kidney failure, and other complications[1][2][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lisinopril + hydrochlorothiazide.